Expanding CAR T-cell therapies remains a critical objective amid challenges managing cytokine release syndrome (CRS) and neurotoxicity (ICANS). Industry leaders emphasize strategies to broaden patient access while preparing for a wave of T-cell therapies. Concurrently, Cellares’ Cell Q platform showcases progress in automating commercial-scale quality control, supporting scalability of cell therapies including CAR T. These developments underscore dynamic efforts to enhance both clinical delivery and manufacturing of transformative cellular immunotherapies.